Singletto
Singletto is a Seattle-based materials science company developing Oxafence Active Protection™, a photodynamic antimicrobial platform that generates singlet oxygen to inactivate pathogens on contact. It sells FDA-cleared virus-inactivating surgical masks and licenses the technology to manufacturing, defense, and healthcare partners.
- Company typePrivate
- Founded2020
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Singletto does
Singletto Inc. is a Seattle-based materials science and biotechnology company founded in 2020 by surgeons Dr. James Chen and Dr. Thomas Lendvay to commercialize photodynamic antimicrobial technology. The company develops and licenses Oxafence Active Protection™, a materials-applied platform that uses light-activated protective dyes (Methylene Blue and Riboflavin) to generate singlet oxygen at material surfaces, inactivating bacteria, viruses, and fungi on contact. The platform's first commercial product is the FDA-cleared (K231741) ProGear Surgical Mask with Oxafence, which inactivates 99.9% of tested viruses (H1N1 Influenza, OC43 human Coronavirus) within five minutes on the outer mask surface when exposed to normal indoor light.
Singletto operates a hybrid business model combining direct-to-consumer hardware sales through Amazon, B2B technology licensing to manufacturing partners (e.g., Prestige Ameritech) for integration into PPE, uniforms, bandages, and tissues, and enterprise/government engagement with the U.S. Department of Defense (including DARPA programs) and healthcare systems in the U.S. and New Zealand. Manufacturing is outsourced to partner Prestige Ameritech, allowing Singletto to focus on R&D, regulatory, and platform licensing. The company has filed seven provisional patents, holds registered trademarks for Oxafence and Singletto, and has secured $10 million in Series A funding (October 2025) with U.S. Department of Defense backing, building on earlier SEC-registered exempt offerings.
The company's customer base spans healthcare workers (FDA-cleared clinical masks), military/operational users (DARPA programs evaluating warfighter biological protection and wound care), general consumers (Amazon D2C), and manufacturing licensees. With 1–10 employees and a team of approximately 18 named executives, scientists, advisors, and operational staff, Singletto is positioned as an early-stage platform company at the intersection of translational clinical science, regulatory-grade medical products, and B2B materials licensing.
Singletto firmographics
Firmographics- Name
- Singletto
- Legal name
- Singletto Inc.
- Website
- https://singletto.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Singletto is a Seattle-based materials science company developing Oxafence Active Protection™, a photodynamic antimicrobial platform that generates singlet oxygen to inactivate pathogens on contact. It sells FDA-cleared virus-inactivating surgical masks and licenses the technology to manufacturing, defense, and healthcare partners.
- Ownership category
- akta.pro rank
Singletto industry classification
Industry- Product category
- Antimicrobial Materials Technology & Personal Protective Equipment
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields) (HLAHANAF)
- akta.pro secondary industry
- PPE, Safety & Infection Control Supplies Distribution (JanSan-adjacent) (CRAOAGAK)
Keywords
Where Singletto is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Singletto business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Product Sales (Face Masks): Direct-to-consumer and B2B sales of FDA-cleared ProGear Surgical Masks with Oxafence through Amazon and healthcare distribution channels.
- Technology Licensing: Licensing the Oxafence Active Protection platform to manufacturing partners for integration into PPE, uniforms, bandages, tissues, and other everyday products. Singletto develops and licenses the technology designed for integration into existing products and manufacturing processes.
- Partner Manufacturing: Working with manufacturing partners (e.g., Prestige Ameritech) to produce Oxafence-integrated products, with Singletto focusing on enabling new capabilities in materials rather than manufacturing end products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | ProGear Surgical Mask with Oxafence available for direct consumer purchase on Amazon |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels3 records
Singletto product offering
Product offeringCore offering
Singletto develops the Oxafence Active Protection™ platform, a metal-free, materials-applied antimicrobial technology that uses photosensitizer chemistry (Methylene Blue and Riboflavin) to generate singlet oxygen at material surfaces under normal indoor light, inactivating viruses, bacteria, and fungi on contact. Its first commercial product is the FDA-cleared ProGear Surgical Mask with Oxafence, sold directly to consumers on Amazon and to healthcare systems, while Singletto separately licenses the Oxafence platform to manufacturing partners for integration into PPE, uniforms, bandages, tissues, and other everyday products.
Product overview
Singletto is a technology company that developed Oxafence Active Protection™, a materials-applied antimicrobial technology platform. The core platform uses light-activated protective dyes (Methylene Blue and Riboflavin) that generate singlet oxygen when exposed to normal indoor light, enabling active pathogen inactivation directly within materials during use. The first commercial product is the ProGear Surgical Mask with Oxafence (FDA-cleared K231741), which is sold on Amazon and available in the U.S. and New Zealand. Singletto operates as both a product company and a licensing platform, working with manufacturing partners like Prestige Ameritech to integrate Oxafence into various products across healthcare, military, and consumer applications. The company is headquartered in Seattle, Washington.
Differentiator
Problem solved
Functional benefit
Brands
- Oxafence Active Protection: Singletto's materials-applied antimicrobial technology platform that enables antimicrobial performance directly within materials, using light-activated protective dyes to generate singlet oxygen that inactivates pathogens.
Products and services
- Oxafence Active Protection™ Singletto's materials-applied antimicrobial technology platform that uses light-activated protective dyes (Methylene Blue and Riboflavin) to generate singlet oxygen at material surfaces under normal indoor light, inactivating viruses, bacteria, and fungi on contact. Designed for integration into existing materials and manufacturing processes across healthcare, military, and consumer product categories.
- ProGear Surgical Mask with Oxafence FDA-cleared surgical mask (K231741) incorporating Oxafence technology that inactivates 99.9% of H1N1 Influenza and 99.99% of Betacoronavirus 1 OC43 within 5 minutes on the outer surface under normal indoor light. Sold to consumers on Amazon and to healthcare systems in the U.S. and New Zealand; manufactured in partnership with Prestige Ameritech.
- Oxafence Technology Licensing Licensing program through which Singletto provides its Oxafence Active Protection™ materials-applied antimicrobial ingredient technology to manufacturing partners for integration into their existing products and manufacturing processes. Targeted at manufacturers of PPE, uniforms, bandages, tissues, and other everyday products seeking active virus-inactivating and antimicrobial performance.
Quantifiable outcome
- 99.9% inactivation of H1N1 Influenza within 5 minutes on treated mask surface
- +3 more outcomes
Companies that use Singletto
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Singletto technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Singletto partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and minor.
- Teledyne FLIRcoreSingletto supported Teledyne FLIR in the U.S. Defense Advanced Research Projects Agency (DARPA) PPB Program
- DARPAflagshipSelected for DARPA's Embedded Entrepreneur Initiative (EEI); previously participated in DARPA's Personal Protection Biosystem program evaluating next-generation approaches to warfighter protection from biological threats
- Kenyan Healthcare OrganizationsminorPartnership with Kenyan healthcare organizations on TB (tuberculosis) research
- U.S. Department of DefenseflagshipU.S. Department of Defense-supported initiatives including DARPA programs; technology recognized for potential in warfighter protection and wound care applications
- World Health OrganizationflagshipWHO task force-organized DeMaND study (Development of Methods for Mask and N95 Decontamination); Singletto co-founders led global consortium of academic, public health, and government laboratories; MBL method included in WHO PPE guidelines
- University of Washington / CoMotioncoreSingletto co-founders affiliated with UW; received funding through UW's CoMotion innovation center (Amazon Catalyst Award); research conducted through Seattle Children's Research Institute
- University of Calgary (Belinda Heyne)coreOngoing research collaboration; Dr. Belinda Heyne, Professor of Chemistry, contributed to DeMaND study and continues research as part of Singletto Labs; Heyne Lab is one of few labs worldwide capable of measuring singlet oxygen directly
- Global Research Consortium (13 institutions)coreWHO-led DeMaND study consortium included 13 institutions and 52 researchers worldwide; involved CDC, WHO, University of Calgary, University of Alberta, Université Laval, Stanford, University of Washington, and others
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Singletto competitors and assessment
Company assessmentDirect peers
- Livinguard: Livinguard develops antimicrobial textile and surface technologies that inactivate pathogens on contact, directly comparable to Singletto's Oxafence platform in target use cases (face masks, PPE, consumer textiles) and value proposition.
- HeiQ Materials: HeiQ is an established antimicrobial and material science company that licenses technology to textile and PPE manufacturers, with overlapping business model (technology licensing into manufacturing partners) and overlapping customer base in healthcare and consumer textiles.
- BioCote: BioCote licenses antimicrobial technology (silver-ion-based) into plastics, textiles, coatings, and consumer products. Closely comparable business model to Singletto's planned licensing platform across manufacturers of everyday materials.
Broad incumbents
- Microban International: Microban is a major incumbent in built-in antimicrobial technologies serving consumer products, textiles, and healthcare. Comparable to Singletto as a platform antimicrobial licensor, though operating at much broader scale and with chemistries (silver, zinc) different from Oxafence's photodynamic approach.
- 3M (Healthcare/Personal Safety): 3M is the dominant global PPE and respirator manufacturer. While not a direct antimicrobial technology licensor, it is a key incumbent in the face mask market where Singletto competes and a potential channel partner or competitor for embedded antimicrobial applications.
- Honeywell Personal Protective Equipment: Honeywell's PPE division manufactures respirators, surgical masks, and protective equipment used in healthcare and industrial settings. Comparable as a broad incumbent in Singletto's primary end market.
- Ansell: Ansell is a global leader in medical and industrial gloves and protective solutions, including surgical and examination PPE. Comparable as a healthcare and industrial PPE incumbent that could be either a licensing partner or competitor.
Regional players
- Prestige Ameritech: Prestige Ameritech is the largest domestic U.S. manufacturer of surgical masks and respirators and is Singletto's manufacturing partner for ProGear masks. Comparable as a face mask producer, though not a technology licensor.
- Medicom: Medicom is a global manufacturer of single-use infection-prevention products including face masks, with comparable product category and healthcare distribution channels.
Emerging players
- Copper Clothing: Copper Clothing develops copper-infused antimicrobial textiles and PPE. Comparable as an emerging antimicrobial materials company pursuing similar healthcare and consumer applications with a different active chemistry.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Singletto social profiles
Digital presenceSingletto compliance and trust
Trust signalCompliance2 records
Singletto financial estimates
Financial estimateRevenue estimate
Valuation estimate
Singletto leadership team
Management profileNumber of profiles
Profiles18 records
Singletto funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Singletto M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Singletto
What does Singletto do?
Singletto develops the Oxafence Active Protection™ platform, a metal-free, materials-applied antimicrobial technology that uses photosensitizer chemistry (Methylene Blue and Riboflavin) to generate singlet oxygen at material surfaces under normal indoor light, inactivating viruses, bacteria, and fungi on contact. Its first commercial product is the FDA-cleared ProGear Surgical Mask with Oxafence, sold directly to consumers on Amazon and to healthcare systems, while Singletto separately licenses the Oxafence platform to manufacturing partners for integration into PPE, uniforms, bandages, tissues, and other everyday products.
Is Singletto a public or private company?
Singletto is a private company. It is classified as venture growth investor backed and is currently operating.
When was Singletto founded?
Singletto was founded in 2020. It employs 1 to 10 people.
Where is Singletto based?
Singletto is headquartered in Seattle, United States, in the North America region.
How does Singletto make money?
Three revenue lines are on record. Product Sales (Face Masks) is the primary driver. The others are technology Licensing and partner Manufacturing.
Who are Singletto's main competitors?
Direct peers on record are Livinguard, HeiQ Materials and BioCote. Broad incumbents are Microban International, 3M (Healthcare/Personal Safety), Honeywell Personal Protective Equipment and Ansell. Regional players are Prestige Ameritech and Medicom. Copper Clothing is listed as an emerging player.
Does Singletto have an API?
No public API is recorded for Singletto.
What industry is Singletto in?
Singletto's product category is Antimicrobial Materials Technology & Personal Protective Equipment. Its primary akta.pro industry code is HLAHANAF, Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields), with a secondary code of CRAOAGAK, PPE, Safety & Infection Control Supplies Distribution (JanSan-adjacent). Its NAICS code is 339113 and its SIC code is 3841.